Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Extols NHS Asset In The ‘No Plan B’ Post-Brexit World

Executive Summary

The UK medtech industry is in a state of flux given the known unknowns of Brexit, perennial health-care funding pressures that will only exacerbate, and a menu of cost-saving initiatives that require medtech companies to adjust how they work with the National Health Service. Improving NHS and its role as a boon to smaller UK medtech companies is an important priority of industry.


Related Content

UK Viewpoint: AHSNs, AAR And Accelerators – Market Access & Innovation Update
UK Medtechs Look Beyond Brexit To Long-Term Life-Science Strategy
UK Looks To Model New Medtech Strategy On US Successes
New Barrier For UK’s Brexit Plans; Industry Looks For Potential Opportunities
UK Accelerated Access Review Can Create A Post-Brexit 'Medtech Powerhouse'





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts